CircITGB6 promotes ovarian cancer cisplatin resistance by resetting tumor-associated macrophage polarization toward the M2 phenotype.
Li H, Luo F, Jiang X, Zhang W, Xiang T, Pan Q, Cai L, Zhao J, Weng D, Li Y, Dai Y, Sun F, Yang C, Huang Y, Yang J, Tang Y, Han Y, He M, Zhang Y, Song L, Xia JC.
J Immunother Cancer. 2022 Mar;10(3):e004029. doi: 10.1136/jitc-2021-004029.
Prognostic and Theranostic Biomarkers in Ovarian Clear Cell Carcinoma.
Wiedemeyer K, Wang L, Kang EY, Liu S, Ou Y, Kelemen LE, Feil L, Anglesio MS, Glaze S, Ghatage P, Nelson GS, Köbel M.
Int J Gynecol Pathol. 2022 Mar 1;41(2):168-179. doi: 10.1097/PGP.0000000000000780.
Novel LAMC2 fusion protein has tumor-promoting properties in ovarian carcinoma.
Daisuke H, Kato H, Fukumura K, Mayeda A, Miyagi Y, Seiki M, Koshikawa N.
Cancer Sci. 2021 Dec;112(12):4957-4967. doi: 10.1111/cas.15149. Epub 2021 Nov 5.
'STIC-like' lesions in ovarian low-grade serous carcinoma: a diagnostic pitfall.
Machuca-Aguado J, McCluggage WG.
Histopathology. 2023 Sep;83(3):489-492. doi: 10.1111/his.14967. Epub 2023 Jun 25.
Ovarian carcinoma in situ with germline BRCA1 mutation and loss of heterozygosity at BRCA1 and TP53.
Werness BA, Parvatiyar P, Ramus SJ, Whittemore AS, Garlinghouse-Jones K, Oakley-Girvan I, DiCioccio RA, Wiest J, Tsukada Y, Ponder BA, Piver MS.
J Natl Cancer Inst. 2000 Jul 5;92(13):1088-91. doi: 10.1093/jnci/92.13.1088.
HER2 status as a potential predictive biomarker for ovarian clear cell carcinoma.
Kendall Bártů M, Němejcová K, Michálková R, Stružinská I, Hájková N, Hojný J, Krkavcová E, Laco J, Matěj R, Drozenová J, Méhes G, Fabian P, Hausnerová J, Švajdler M, Škapa P, Cibula D, Zima T, Dundr P.
Virchows Arch. 2023 Oct;483(4):497-507. doi: 10.1007/s00428-023-03640-4. Epub 2023 Sep 7.
Cytoreductive surgery in ovarian cancer.
Pomel C, Jeyarajah A, Oram D, Shepherd J, Milliken D, Dauplat J, Reynolds K.
Cancer Imaging. 2007 Dec 17;7(1):210-5. doi: 10.1102/1470-7330.2007.0030.
Early and consistent overexpression of ADRM1 in ovarian high-grade serous carcinoma.
Jiang RT, Yemelyanova A, Xing D, Anchoori RK, Hamazaki J, Murata S, Seidman JD, Wang TL, Roden RBS.
J Ovarian Res. 2017 Aug 7;10(1):53. doi: 10.1186/s13048-017-0347-y.
SOX2 expression and prognostic significance in ovarian carcinoma.
Pham DL, Scheble V, Bareiss P, Fischer A, Beschorner C, Adam A, Bachmann C, Neubauer H, Boesmueller H, Kanz L, Wallwiener D, Fend F, Lengerke C, Perner S, Fehm T, Staebler A.
Int J Gynecol Pathol. 2013 Jul;32(4):358-67. doi: 10.1097/PGP.0b013e31826a642b.
Management of Preinvasive Lesions.
Patrono MG, Corzo C, Iniesta M, Ramirez PT.
Clin Obstet Gynecol. 2017 Dec;60(4):771-779. doi: 10.1097/GRF.0000000000000316.
